xml: <clinical_study>
    <!-- This xml conforms to an XML Schema at:
      https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
    <required_header>
      <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
      <link_text>Link to the current ClinicalTrials.gov record.</link_text>
      <url>https://clinicaltrials.gov/ct2/show/NCT05974930</url>
    </required_header>
    <id_info>
      <org_study_id>69589</org_study_id>
      <nct_id>NCT05974930</nct_id>
    </id_info>
    <brief_title>Intravascular ULTRAsound-Guided PCI in Patients With ST-Elevation Myocardial Infarction</brief_title>
    <acronym>ULTRA-STEMI</acronym>
    <official_title>Intravascular ULTRAsound-Guided PCI in Patients With ST-Elevation Myocardial Infarction: the ULTRA-STEMI Trial</official_title>
    <sponsors>
      <lead_sponsor>
        <agency>Aristotle University Of Thessaloniki</agency>
        <agency_class>Other</agency_class>
      </lead_sponsor>
    </sponsors>
    <source>Aristotle University Of Thessaloniki</source>
    <oversight_info>
      <has_dmc>No</has_dmc>
      <is_fda_regulated_drug>No</is_fda_regulated_drug>
      <is_fda_regulated_device>Yes</is_fda_regulated_device>
      <is_us_export>Yes</is_us_export>
    </oversight_info>
    <brief_summary>
      <textblock>
        The main goal of the ULTRA-STEMI trial is to investigate the prognostic impact of IVUS-guided&#xD;
        PCI in patients with STEMI and correlate IVUS measurements with clinical, procedural, imaging&#xD;
        and follow-up outcomes of interest.&#xD;
  &#xD;
        Study participants will undergo primary PCI as per standardized procedures; IVUS will be&#xD;
        performed at baseline, post-intervention and post-optimization. Manual thrombus aspiration&#xD;
        will be performed according to clinical indications. The aspirated thrombi will be collected&#xD;
        and scanned with micro-computed tomography (micro-CT). Also, angiographic and peri-procedural&#xD;
        data will be gathered. Post-PCI instantaneous wave-free ratio (IFR) will also be performed to&#xD;
        assess the severity of the residual coronary-artery stenosis, if any. All patients will be&#xD;
        followed up for at least12 months for the adjudication of major adverse cardiovascular&#xD;
        events.&#xD;
      </textblock>
    </brief_summary>
    <detailed_description>
      <textblock>
        The ULTRA-STEMI trial is a prospective investigator-initiated single-centre single-arm&#xD;
        observational cohort study aiming to enroll 80 consecutive patients presenting with&#xD;
        ST-segment elevation myocardial infarction (STEMI) and undergoing IVUS-guided primary PCI.&#xD;
        IVUS will be performed at baseline, post-intervention and post-optimization. Baseline tissue&#xD;
        characterization includes the morphological description of culprit lesion plaque and thrombus&#xD;
        characteristics as assessed with IVUS. In patients with large thrombus burden, manual&#xD;
        thrombus aspiration will be performed according to clinical indications. The aspirated&#xD;
        thrombi will be collected and scanned with micro-computed tomography (micro-CT) to correlate&#xD;
        IVUS measurements with micro-CT thrombus quantification. Also, angiographic data will be&#xD;
        gathered to correlate IVUS measurements with pre-and post-PCI angiographic information.&#xD;
        Post-PCI instantaneous wave-free ratio (IFR) will also be performed to assess the severity of&#xD;
        the residual coronary-artery stenosis, if any. All patients will be followed up for at least&#xD;
        12 months for the adjudication of major adverse cardiovascular events.The primary endpoint&#xD;
        will be target vessel failure at 12 months (defined as a composite of cardiac death, target&#xD;
        vessel myocardial infarction and clinically driven target vessel revascularization). The&#xD;
        secondary outcomes of interest will be: radiation exposure, contrast use and kidney function&#xD;
        effects. Other endpoints include clinical and angiographic outcomes along with post-PCI IVUS,&#xD;
        iFR and micro-CT findings.&#xD;
      </textblock>
    </detailed_description>
    <overall_status>Not yet recruiting</overall_status>
    <start_date type="Anticipated">October 1, 2023</start_date>
    <completion_date type="Anticipated">December 30, 2025</completion_date>
    <primary_completion_date type="Anticipated">October 1, 2024</primary_completion_date>
    <study_type>Observational</study_type>
    <has_expanded_access>No</has_expanded_access>
    <study_design_info>
      <observational_model>Cohort</observational_model>
      <time_perspective>Prospective</time_perspective>
    </study_design_info>
    <primary_outcome>
      <measure>Rate of &quot;Target vessel failure&quot; at 12 months of follow-up in association with IVUS measurements</measure>
      <time_frame>2 years</time_frame>
      <description>Follow-up will be obtained using online patient-reported outcome measurements by email or standardized telephone calls at 30 days, 6 months and 12 months after the procedure. Primary follow-up outcome of interest is the composite endpoint of target vessel failure (cardiac death, new-onset heart failure, target vessel myocardial infarction, clinically driven target vessel revascularization or target lesion revascularization).</description>
    </primary_outcome>
    <primary_outcome>
      <measure>All-cause mortality at 12 months of follow-up in association with IVUS measurements</measure>
      <time_frame>2 years</time_frame>
      <description>Co-primary study outcome will be the investigation of all-cause mortality (i.e., death from any cause) after hospitalization and during follow-up.</description>
    </primary_outcome>
    <secondary_outcome>
      <measure>In-hospital (post-PCI) adverse events in association with IVUS measurements</measure>
      <time_frame>2 years</time_frame>
      <description>The composite endpoint of in-hospital (post-PCI) adverse events includes: cardiac tamponade, need for CABG, shock, in-hospital mortality, acute kidney failure, bleeding, stroke.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Pre-procedural angiographic outcomes in association with IVUS measurements</measure>
      <time_frame>2 years</time_frame>
      <description>Pre-procedural Thrombolysis in myocardial infarction (TIMI) flow, thrombus burden classification, culprit vessel, number of diseased vessels, and the SYNergy between percutaneous intervention with TAXus DES and cardiac surgery (SYNTAX) score will be recorded and associated with pre-procedural IVUS measurements. Higher SYNTAX score and lower TIMI flow represent greater obstruction in the diseased vessels.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Post-procedural angiographic outcomes in association with IVUS measurements</measure>
      <time_frame>2 years</time_frame>
      <description>Post-procedural TIMI flow, angiographically evident residual thrombus, no-reflow phenomenon, myocardial blush grade, and distal embolization will be recorded and associated with IVUS measurements.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Post-PCI iFR measurement in association with IVUS measurements</measure>
      <time_frame>2 years</time_frame>
      <description>iFR=ratio of distal coronary pressure (Pd) to the aortic pressure (Pa) during an isolated period during diastole.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Microtomographic thrombus volume in association with IVUS measurements</measure>
      <time_frame>2 years</time_frame>
      <description>Micro-CT derived volume of the extracted thrombotic material will be correlated with IVUS measurements.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Microtomographic thrombus porosity in association with IVUS measurements</measure>
      <time_frame>2 years</time_frame>
      <description>Micro-CT derived porosity of the extracted thrombotic material will be correlated with IVUS measurements.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Microtomographic thrombus density in association with IVUS measurements</measure>
      <time_frame>2 years</time_frame>
      <description>Micro-CT derived density of the extracted thrombotic material will be correlated with IVUS measurements.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Νumber and type of stents in association with IVUS measurements</measure>
      <time_frame>2 years</time_frame>
      <description>Νumber and type of stents used will be recorded and associated with IVUS measurements.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Stent length and diameter in association with IVUS measurements</measure>
      <time_frame>2 years</time_frame>
      <description>Stent length and diameter will be recorded and associated with IVUS measurements.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Contrast volume in association with IVUS measurements</measure>
      <time_frame>2 years</time_frame>
      <description>Volume of the contrast used will be recorded and associated with IVUS measurements.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Radiation dose in association with IVUS measurements</measure>
      <time_frame>2 years</time_frame>
      <description>Peri-procedural radiation dose will be recorded and associated with IVUS measurements.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Procedural duration in association with IVUS measurements</measure>
      <time_frame>2 years</time_frame>
      <description>Procedural duration will be recorded and associated with IVUS measurements.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Post-PCI stent underexpansion, deformation or malapposition in association with baseline IVUS measurements</measure>
      <time_frame>2 years</time_frame>
      <description>Stent underexpansion, deformation or malapposition (yes/no) will be recorded and associated with baseline IVUS measurements.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Post-PCI edge dissection in association with baseline IVUS measurements</measure>
      <time_frame>2 years</time_frame>
      <description>Edge dissection (yes/no) will be recorded and associated with baseline IVUS measurements.</description>
    </secondary_outcome>
    <secondary_outcome>
      <measure>Post-PCI high plaque burden at stent edges, residual focal lesions or tissue protrusion through the stent struts in association with baseline IVUS measurements</measure>
      <time_frame>2 years</time_frame>
      <description>High plaque burden at stent edges, residual focal lesions or tissue protrusion through the stent struts (yes/no) will be recorded and associated with baseline IVUS measurements.</description>
    </secondary_outcome>
    <number_of_groups>1</number_of_groups>
    <enrollment type="Anticipated">80</enrollment>
    <condition>STEMI</condition>
    <condition>Intravascular Imaging</condition>
    <condition>IVUS</condition>
    <arm_group>
      <arm_group_label>Patients with STEMI undergoing IVUS-guided primary PCI</arm_group_label>
      <description>The ULTRA-STEMI trial will include consecutive patients with STEMI undergoing IVUS-guided primary PCI. All participants will undergo: IVUS intra-coronary imaging at baseline-, post-intervention and post-optimization. If manual thrombus aspiration is needed, the aspirated thrombotic material will be collected to be micro-CT scanned. Post-PCI iFR will be also performed in each participant. Clinical, angiographic and peri-procedural data will be collected. Each participant will be subject to telephone follow-up at 1, 6 and 12 months.</description>
    </arm_group>
    <intervention>
      <intervention_type>Device</intervention_type>
      <intervention_name>IVUS imaging for primary PCI guidance</intervention_name>
      <description>Eagle Eye Platinum Intravascular ultrasound (IVUS) will be used to assess intra-coronary plaque, thrombus or stenosis in patients with STEMI. The device is FDA- and EMA-approved and routinely used in clinical practice. Quantitative and qualitative IVUS parameters will be collected and recorded for all participants to be correlated with clinical, imaging and angiographic outcomes of interest.</description>
      <arm_group_label>Patients with STEMI undergoing IVUS-guided primary PCI</arm_group_label>
    </intervention>
    <biospec_retention>Samples With DNA</biospec_retention>
    <biospec_descr>
      <textblock>
        Aspirated thrombotic samples (in cases with large thrombus burden) will be collected to&#xD;
        undergo micro-CT scanning.&#xD;
      </textblock>
    </biospec_descr>
    <eligibility>
      <study_pop>
        <textblock>
          All adult patients presenting with STEMI undergoing primary PCI for a native coronary&#xD;
          artery culprit lesion will undergo IVUS (at baseline, post-intervention and&#xD;
          post-optimization) and post-PCI iFR.&#xD;
        </textblock>
      </study_pop>
      <sampling_method>Non-Probability Sample</sampling_method>
      <criteria>
        <textblock>
          Inclusion Criteria:&#xD;
  &#xD;
            1. Patients with acute STEMI undergoing primary PCI within 12 hours of symptom onset&#xD;
               according to the 4th universal definition of myocardial infarction.&#xD;
  &#xD;
            2. Age &gt;18 years&#xD;
  &#xD;
            3. Individuals willing to voluntarily sign the consent and data protection forms before&#xD;
               their inclusion in the clinical study.&#xD;
  &#xD;
          Exclusion Criteria:&#xD;
  &#xD;
            1. Patients presenting with cardiogenic shock&#xD;
  &#xD;
            2. Patients with a known contraindication for primary PCI&#xD;
  &#xD;
            3. Pregnancy&#xD;
  &#xD;
            4. Presentation ≥12 hours after symptom onset&#xD;
        </textblock>
      </criteria>
      <gender>All</gender>
      <minimum_age>18 Years</minimum_age>
      <maximum_age>N/A</maximum_age>
      <healthy_volunteers>No</healthy_volunteers>
    </eligibility>
    <overall_official>
      <last_name>Georgios Kassimis, MD, PhD</last_name>
      <role>Principal Investigator</role>
      <affiliation>2ND Cardiology Department, Hippokrateion General Hospital of Thessaloniki, Greece</affiliation>
    </overall_official>
    <overall_contact>
      <last_name>Georgios Kassimis, MD, PhD</last_name>
      <phone>+306936693916</phone>
      <email>gksup@yahoo.gr</email>
    </overall_contact>
    <overall_contact_backup>
      <last_name>Efstratios Karagiannidis, MD, PhD</last_name>
      <phone>+306938943309</phone>
      <email>stratoskarag@gmail.com</email>
    </overall_contact_backup>
    <reference>
      <citation>Groenland FTW, Mahmoud KD, Neleman T, Ziedses des Plantes AC, Scoccia A, Ligthart J, Witberg KT, Nuis RJ, den Dekker WK, Wilschut JM, Diletti R, Zijlstra F, Kardys I, Cummins P, Van Mieghem NM, Daemen J. Tissue characterisation and primary percutaneous coronary intervention guidance using intravascular ultrasound: rationale and design of the SPECTRUM study. Open Heart. 2022 Apr;9(1):e001955. doi: 10.1136/openhrt-2021-001955.</citation>
      <PMID>35437257</PMID>
    </reference>
    <reference>
      <citation>Karagiannidis E, Papazoglou AS, Sofidis G, Chatzinikolaou E, Keklikoglou K, Panteris E, Kartas A, Stalikas N, Zegkos T, Girtovitis F, Moysidis DV, Stefanopoulos L, Koupidis K, Hadjimiltiades S, Giannakoulas G, Arvanitidis C, Michaelson JS, Karvounis H, Sianos G. Micro-CT-Based Quantification of Extracted Thrombus Burden Characteristics and Association With Angiographic Outcomes in Patients With ST-Elevation Myocardial Infarction: The QUEST-STEMI Study. Front Cardiovasc Med. 2021 Apr 21;8:646064. doi: 10.3389/fcvm.2021.646064. eCollection 2021.</citation>
      <PMID>33969012</PMID>
    </reference>
    <reference>
      <citation>Didagelos M, Pagiantza A, Zegkos T, Zarra K, Angelopoulos V, Kouparanis A, Peteinidou E, Kassimis G, Karvounis H, Ziakas A. Low Molecular Weight Heparin in Improving RAO After Transradial Coronary Catheterization: The LOW-RAO Randomized Study. JACC Cardiovasc Interv. 2022 Aug 22;15(16):1686-1688. doi: 10.1016/j.jcin.2022.05.047. Epub 2022 Jul 27. No abstract available.</citation>
      <PMID>35981848</PMID>
    </reference>
    <verification_date>July 2023</verification_date>
    <study_first_submitted>July 16, 2023</study_first_submitted>
    <study_first_submitted_qc>July 25, 2023</study_first_submitted_qc>
    <study_first_posted type="Actual">August 3, 2023</study_first_posted>
    <last_update_submitted>July 25, 2023</last_update_submitted>
    <last_update_submitted_qc>July 25, 2023</last_update_submitted_qc>
    <last_update_posted type="Actual">August 3, 2023</last_update_posted>
    <responsible_party>
      <responsible_party_type>Principal Investigator</responsible_party_type>
      <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
      <investigator_full_name>Karagiannidis Efstratios</investigator_full_name>
      <investigator_title>Principal Investigator</investigator_title>
    </responsible_party>
    <keyword>IVUS</keyword>
    <keyword>Thrombus</keyword>
    <keyword>STEMI</keyword>
    <condition_browse>
      <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
      <mesh_term>Myocardial Infarction</mesh_term>
      <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
      <mesh_term>Infarction</mesh_term>
    </condition_browse>
    <patient_data>
      <sharing_ipd>Undecided</sharing_ipd>
    </patient_data>
    <!-- Results have not yet been posted for this study                                          -->
  </clinical_study>
  
  
text: download date: ClinicalTrials.gov processed this data on September 20, 2023
  link text: Link to the current ClinicalTrials.gov record.
  url: https://clinicaltrials.gov/ct2/show/NCT05974930
  org study id: 69589
  nct id: NCT05974930
  lead sponsor: 
  has dmc: No
  is fda regulated drug: No
  is fda regulated device: Yes
  is us export: Yes
  The main goal of the ULTRA-STEMI trial is to investigate the prognostic impact of IVUS-guided
        PCI in patients with STEMI and correlate IVUS measurements with clinical, procedural, imaging
        and follow-up outcomes of interest.
  
        Study participants will undergo primary PCI as per standardized procedures; IVUS will be
        performed at baseline, post-intervention and post-optimization. Manual thrombus aspiration
        will be performed according to clinical indications. The aspirated thrombi will be collected
        and scanned with micro-computed tomography (micro-CT). Also, angiographic and peri-procedural
        data will be gathered. Post-PCI instantaneous wave-free ratio (IFR) will also be performed to
        assess the severity of the residual coronary-artery stenosis, if any. All patients will be
        followed up for at least12 months for the adjudication of major adverse cardiovascular
        events.
  The ULTRA-STEMI trial is a prospective investigator-initiated single-centre single-arm
        observational cohort study aiming to enroll 80 consecutive patients presenting with
        ST-segment elevation myocardial infarction (STEMI) and undergoing IVUS-guided primary PCI.
        IVUS will be performed at baseline, post-intervention and post-optimization. Baseline tissue
        characterization includes the morphological description of culprit lesion plaque and thrombus
        characteristics as assessed with IVUS. In patients with large thrombus burden, manual
        thrombus aspiration will be performed according to clinical indications. The aspirated
        thrombi will be collected and scanned with micro-computed tomography (micro-CT) to correlate
        IVUS measurements with micro-CT thrombus quantification. Also, angiographic data will be
        gathered to correlate IVUS measurements with pre-and post-PCI angiographic information.
        Post-PCI instantaneous wave-free ratio (IFR) will also be performed to assess the severity of
        the residual coronary-artery stenosis, if any. All patients will be followed up for at least
        12 months for the adjudication of major adverse cardiovascular events.The primary endpoint
        will be target vessel failure at 12 months (defined as a composite of cardiac death, target
        vessel myocardial infarction and clinically driven target vessel revascularization). The
        secondary outcomes of interest will be: radiation exposure, contrast use and kidney function
        effects. Other endpoints include clinical and angiographic outcomes along with post-PCI IVUS,
        iFR and micro-CT findings.
  observational model: Cohort
  time perspective: Prospective
  measure: Rate of "Target vessel failure" at 12 months of follow-up in association with IVUS measurements
  time frame: 2 years
  description: Follow-up will be obtained using online patient-reported outcome measurements by email or standardized telephone calls at 30 days, 6 months and 12 months after the procedure. Primary follow-up outcome of interest is the composite endpoint of target vessel failure (cardiac death, new-onset heart failure, target vessel myocardial infarction, clinically driven target vessel revascularization or target lesion revascularization).
  measure: All-cause mortality at 12 months of follow-up in association with IVUS measurements
  time frame: 2 years
  description: Co-primary study outcome will be the investigation of all-cause mortality (i.e., death from any cause) after hospitalization and during follow-up.
  measure: In-hospital (post-PCI) adverse events in association with IVUS measurements
  time frame: 2 years
  description: The composite endpoint of in-hospital (post-PCI) adverse events includes: cardiac tamponade, need for CABG, shock, in-hospital mortality, acute kidney failure, bleeding, stroke.
  measure: Pre-procedural angiographic outcomes in association with IVUS measurements
  time frame: 2 years
  description: Pre-procedural Thrombolysis in myocardial infarction (TIMI) flow, thrombus burden classification, culprit vessel, number of diseased vessels, and the SYNergy between percutaneous intervention with TAXus DES and cardiac surgery (SYNTAX) score will be recorded and associated with pre-procedural IVUS measurements. Higher SYNTAX score and lower TIMI flow represent greater obstruction in the diseased vessels.
  measure: Post-procedural angiographic outcomes in association with IVUS measurements
  time frame: 2 years
  description: Post-procedural TIMI flow, angiographically evident residual thrombus, no-reflow phenomenon, myocardial blush grade, and distal embolization will be recorded and associated with IVUS measurements.
  measure: Post-PCI iFR measurement in association with IVUS measurements
  time frame: 2 years
  description: iFR=ratio of distal coronary pressure (Pd) to the aortic pressure (Pa) during an isolated period during diastole.
  measure: Microtomographic thrombus volume in association with IVUS measurements
  time frame: 2 years
  description: Micro-CT derived volume of the extracted thrombotic material will be correlated with IVUS measurements.
  measure: Microtomographic thrombus porosity in association with IVUS measurements
  time frame: 2 years
  description: Micro-CT derived porosity of the extracted thrombotic material will be correlated with IVUS measurements.
  measure: Microtomographic thrombus density in association with IVUS measurements
  time frame: 2 years
  description: Micro-CT derived density of the extracted thrombotic material will be correlated with IVUS measurements.
  measure: Νumber and type of stents in association with IVUS measurements
  time frame: 2 years
  description: Νumber and type of stents used will be recorded and associated with IVUS measurements.
  measure: Stent length and diameter in association with IVUS measurements
  time frame: 2 years
  description: Stent length and diameter will be recorded and associated with IVUS measurements.
  measure: Contrast volume in association with IVUS measurements
  time frame: 2 years
  description: Volume of the contrast used will be recorded and associated with IVUS measurements.
  measure: Radiation dose in association with IVUS measurements
  time frame: 2 years
  description: Peri-procedural radiation dose will be recorded and associated with IVUS measurements.
  measure: Procedural duration in association with IVUS measurements
  time frame: 2 years
  description: Procedural duration will be recorded and associated with IVUS measurements.
  measure: Post-PCI stent underexpansion, deformation or malapposition in association with baseline IVUS measurements
  time frame: 2 years
  description: Stent underexpansion, deformation or malapposition (yes/no) will be recorded and associated with baseline IVUS measurements.
  measure: Post-PCI edge dissection in association with baseline IVUS measurements
  time frame: 2 years
  description: Edge dissection (yes/no) will be recorded and associated with baseline IVUS measurements.
  measure: Post-PCI high plaque burden at stent edges, residual focal lesions or tissue protrusion through the stent struts in association with baseline IVUS measurements
  time frame: 2 years
  description: High plaque burden at stent edges, residual focal lesions or tissue protrusion through the stent struts (yes/no) will be recorded and associated with baseline IVUS measurements.
  arm group label: Patients with STEMI undergoing IVUS-guided primary PCI
  description: The ULTRA-STEMI trial will include consecutive patients with STEMI undergoing IVUS-guided primary PCI. All participants will undergo: IVUS intra-coronary imaging at baseline-, post-intervention and post-optimization. If manual thrombus aspiration is needed, the aspirated thrombotic material will be collected to be micro-CT scanned. Post-PCI iFR will be also performed in each participant. Clinical, angiographic and peri-procedural data will be collected. Each participant will be subject to telephone follow-up at 1, 6 and 12 months.
  intervention type: Device
  intervention name: IVUS imaging for primary PCI guidance
  description: Eagle Eye Platinum Intravascular ultrasound (IVUS) will be used to assess intra-coronary plaque, thrombus or stenosis in patients with STEMI. The device is FDA- and EMA-approved and routinely used in clinical practice. Quantitative and qualitative IVUS parameters will be collected and recorded for all participants to be correlated with clinical, imaging and angiographic outcomes of interest.
  arm group label: Patients with STEMI undergoing IVUS-guided primary PCI
  Aspirated thrombotic samples (in cases with large thrombus burden) will be collected to
        undergo micro-CT scanning.
  study pop: 
  sampling method: Non-Probability Sample
  criteria: 
  gender: All
  minimum age: 18 Years
  maximum age: N/A
  healthy volunteers: No
  last name: Georgios Kassimis, MD, PhD
  role: Principal Investigator
  affiliation: 2ND Cardiology Department, Hippokrateion General Hospital of Thessaloniki, Greece
  last name: Georgios Kassimis, MD, PhD
  phone: +306936693916
  email: gksup@yahoo.gr
  last name: Efstratios Karagiannidis, MD, PhD
  phone: +306938943309
  email: stratoskarag@gmail.com
  citation: Groenland FTW, Mahmoud KD, Neleman T, Ziedses des Plantes AC, Scoccia A, Ligthart J, Witberg KT, Nuis RJ, den Dekker WK, Wilschut JM, Diletti R, Zijlstra F, Kardys I, Cummins P, Van Mieghem NM, Daemen J. Tissue characterisation and primary percutaneous coronary intervention guidance using intravascular ultrasound: rationale and design of the SPECTRUM study. Open Heart. 2022 Apr;9(1):e001955. doi: 10.1136/openhrt-2021-001955.
  PMID: 35437257
  citation: Karagiannidis E, Papazoglou AS, Sofidis G, Chatzinikolaou E, Keklikoglou K, Panteris E, Kartas A, Stalikas N, Zegkos T, Girtovitis F, Moysidis DV, Stefanopoulos L, Koupidis K, Hadjimiltiades S, Giannakoulas G, Arvanitidis C, Michaelson JS, Karvounis H, Sianos G. Micro-CT-Based Quantification of Extracted Thrombus Burden Characteristics and Association With Angiographic Outcomes in Patients With ST-Elevation Myocardial Infarction: The QUEST-STEMI Study. Front Cardiovasc Med. 2021 Apr 21;8:646064. doi: 10.3389/fcvm.2021.646064. eCollection 2021.
  PMID: 33969012
  citation: Didagelos M, Pagiantza A, Zegkos T, Zarra K, Angelopoulos V, Kouparanis A, Peteinidou E, Kassimis G, Karvounis H, Ziakas A. Low Molecular Weight Heparin in Improving RAO After Transradial Coronary Catheterization: The LOW-RAO Randomized Study. JACC Cardiovasc Interv. 2022 Aug 22;15(16):1686-1688. doi: 10.1016/j.jcin.2022.05.047. Epub 2022 Jul 27. No abstract available.
  PMID: 35981848
  responsible party type: Principal Investigator
  investigator affiliation: Aristotle University Of Thessaloniki
  investigator full name: Karagiannidis Efstratios
  investigator title: Principal Investigator
  mesh term: Myocardial Infarction
  mesh term: ST Elevation Myocardial Infarction
  mesh term: Infarction
  sharing ipd: Undecided